The clinical pharmacology of eplerenone

Bibliography

• Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 2001 Fall;19(3):185-200
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240(2):650-6
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989;32(1B):223-7
   PubMedGoogle Scholar
• Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens 1998;11:94A
   Google Scholar
• Pharmaceuticals P. Eplerenone Package Insert
   Google Scholar
• Pharmaceuticals M. Spironolactone Package Insert
   Google Scholar
• White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003;92(1):38-42
   PubMed Web of Science ®Google Scholar
• Prisant LM, Krum H, Roniker B, et al. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003;43(11):1203-10
   PubMed Web of Science ®Google Scholar
• Ravis WR, Reid SE, Ferry J, Tolbert DS. Effect of chronic heart failure on the pharmacokinetics of eplerenone following single and multiple dosing. American Society of Clinical Pharmacologya and Therapeutics Annual Meeting. Miami, Florida; 2004
   Google Scholar
• Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110(5):558-65
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40(9):1596-601
   PubMed Web of Science ®Google Scholar
• Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108(15):1831-8
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-21
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006;70(3):536-42
   PubMed Web of Science ®Google Scholar
• Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diab Care 2005;28(9):2106-12
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15(8):709-16
   PubMed Web of Science ®Google Scholar
• Sawathiparnich P, Murphey LJ, Kumar S, et al. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2003;88(8):3867-73
   PubMed Web of Science ®Google Scholar
• van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens 2006;24(11):2285-92
   PubMed Web of Science ®Google Scholar
• Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007;25(11):2345-51
   PubMed Web of Science ®Google Scholar
• Yalcin AI, Dincer M, Aslan V, Gulbas Z. Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002;25(4):260-4
   PubMed Web of Science ®Google Scholar
• Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76(17):1259-65
   PubMed Web of Science ®Google Scholar
• Cook CS, Berry LM, Kim DH, et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos 2002;30(12):1344-51
   PubMed Web of Science ®Google Scholar
• Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989;29(4):342-7
   PubMed Web of Science ®Google Scholar
• Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62(5):723-31
   PubMed Web of Science ®Google Scholar
• Tolbert DS, Reid SE, Hutmacher MM. The pharmacokinetics of eplerenone in patients with left ventricular dysfunction/heart failure [abstract 27]. Pharmacotherapy 2002;23(10):1332
   Google Scholar
• Cook CS, Berry LM, Bible RH, et al. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 2003;31(11):1448-55
   PubMed Web of Science ®Google Scholar
• Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005;45(7):810-21
   PubMed Web of Science ®Google Scholar
• Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone in special populations [abstract 46]. Pharmacotherapy 2002;22(10):1332
   Google Scholar
• Reid SE, Tolbert DS, Ferry J. The effect of age on the pharmacokinetics of eplerenone [abstract 212]. Pharmacotherapy 2003;23(10):1359
   Google Scholar
• Tolbert DS, Reid SE, Roniker B. Pharmacokinetics of eplerenone coadministered with other medications [abstract 44]. Pharmacotherapy 2002;22(10):1331
   Google Scholar
• Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41(7):1148-55
   PubMed Web of Science ®Google Scholar
• Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005;150(3):426-33
   PubMed Web of Science ®Google Scholar
• Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004;93(8):990-6
   PubMed Web of Science ®Google Scholar
• White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41(5):1021-6
   PubMed Web of Science ®Google Scholar
• Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40(2):117-23
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Tziomalos K, Papageorgiou A, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008;9(4):509-15
   PubMed Web of Science ®Google Scholar
• Pitt B, Gheorghiade M, Zannad F, et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. Eur J Heart Fail 2006;8(3):295-301
   PubMed Web of Science ®Google Scholar
• Pitt B, Ahmed A, Love TE, et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008;52(2):271-8
   PubMed Web of Science ®Google Scholar
• O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008;10(6):492-7
   PubMed Web of Science ®Google Scholar
• Taniguchi I, Kawai M, Date T, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006;70(8):995-1000
   PubMed Web of Science ®Google Scholar
• Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002;25(6):837-42
   PubMed Web of Science ®Google Scholar
• Sato MA, Schoorlemmer GH, Menani JV, et al. Recovery of high blood pressure after chronic lesions of the commissural NTS in SHR. Hypertension 2003;42(4):713-8
   PubMedGoogle Scholar
• Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102(22):2700-6
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37(5):1228-33
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 2000;36(3):838-44
   PubMed Web of Science ®Google Scholar
• Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004;90(7):765-70
   PubMed Web of Science ®Google Scholar
• Feola M, Menardi E, Ribichini F, et al. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. Med Sci Monit 2003;9(8):CR341-5
   Google Scholar
• Ogawa S, Takeuchi K, Mori T, et al. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 2006;33(5-6):477-9
   PubMed Web of Science ®Google Scholar
• Joffe HV, Kwong RY, Gerhard-Herman MD, et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007;92(7):2552-8
   PubMed Web of Science ®Google Scholar
• Roongsritong C, Sutthiwan P, Bradley J, et al. Spironolactone improves diastolic function in the elderly. Clin Cardiol 2005;28(10):484-7
   PubMed Web of Science ®Google Scholar
• Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101(6):594-7
   PubMed Web of Science ®Google Scholar
• Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37(7):1800-7
   PubMed Web of Science ®Google Scholar
• Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007;13(3):170-7
   PubMed Web of Science ®Google Scholar
• Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1(5):940-51
   PubMed Web of Science ®Google Scholar
• Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008;31(1):59-67
   PubMed Web of Science ®Google Scholar
• Dieterich HA, Wendt C, Saborowski F. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. Fiziol Cheloveka 2005;31(6):97-105
   PubMedGoogle Scholar
• Boccanelli A, Mureddu GF, Cacciatore G, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009;11(1):68-76
   PubMed Web of Science ®Google Scholar